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Nuclear events such as chromatin condensation,DNAcleavage at
internucleosomal sites, and histone release from chromatin are rec-
ognized as hallmarks of apoptosis. However, there is no complete
understanding of themolecular events underlying these changes. It
is likely that epigenetic changes such as DNA methylation and his-
tone modifications that are involved in chromatin dynamics and
structure are also involved in the nuclear events described. In this
report we have shown that apoptosis is associated with global DNA
hypomethylation and histone deacetylation events in leukemia
cells. Most importantly, we have observed a particular epigenetic
signature for early apoptosis defined by a release of hypoacetylated
and trimethylated histone H4 and internucleosomal fragmented
DNA that is hypermethylated and originates from perinuclear het-
erochromatin. These findings provide one of the first links between
apoptotic nuclear events and epigenetic markers.
Apoptosis is a form of cell death essential for the morphogenesis,
development, differentiation, and homeostasis of eukaryotic multicel-
lular organisms. The activation of a genetically controlled cell death
program leading to apoptosis results in characteristic biochemical and
morphological features that take place both outside and inside the
nucleus (1). The biochemical mechanisms responsible for key nuclear
events, such as chromatin condensation, DNA fragmentation, and
release of nuclear proteins, although commonly used as markers for
apoptosis, are not fully understood (2). The regulated nature of apopto-
sis makes it likely that nuclear changes experienced by apoptotic cells
aremediated by epigeneticmarkers. This epigenetic information is basi-
cally stored as DNA methylation and post-translational histone modi-
fications. These two groups of modifications play an active role in orga-
nizing, compartmentalizing, and regulating genetic information
encoded in DNA by defining nuclear architecture, and gene expression
(3). With regard to gene regulation, the major functional consequence
of DNAmethylation is the repression of transcription (4). In the case of
histone modifications, the type of modification (acetylation, methyla-
tion, phosphorylation, etc.) and the specific amino acid residue that is
modified determine the functional effect. Histone modifications also
determine the nature of chromatin regions, such as heterochromatin.
For example, the inactive X chromosome is characterized by trimethy-
lation of Lys-27 of H3 and dimethylation of Lys-9 of H3 (5–7), whereas
Lys-9 trimethylation and Lys-27 monomethylation of H3 and Lys-20
trimethylation of H4 are characteristic of pericentric heterochromatin
(8, 9).
In the context of apoptosis, DNA fragmentation and chromatin con-
densation have been associated with changes in histone modifications
(10, 11). For instance, apoptotic phosphorylation of histone H2A, H2B,
and H3, dephosphorylation of histone H1, and H2A deubiquitylation
(12–16) have been associated with DNA fragmentation and chromatin
condensation. These results suggest that a conformational change in
chromatin structure is needed prior to condensation, although the
mechanism and functional significance remain unclear. A global
decrease in histone acetylation in apoptosis has also been reported (17,
18), although some authors have interpreted this result to be a loss of
hyperacetylated histones by degradation rather than the consequence of
the active hypoacetylation of histones during apoptosis (19). Thus, there
is a need to clarify the role of these modifications in different nuclear
events during apoptosis.
Regarding apoptotic release of histones and other nuclear proteins, it
has been proposed that this process is associated with chromatin con-
densation and DNA fragmentation (20, 21). Histone release may not
merely be a simple by-product of chromatin condensation or DNA
fragmentation and could be the result of specific chromatin modifica-
tions in particular nuclear compartments. In fact, during apoptosis a
series of nuclear matrices andmembrane proteins that are fundamental
to the maintenance of internal nuclear structures are degraded by
caspases (22–24). For instance, degradation of nuclear lamins, which
maintain nuclear structure by attaching chromatin to the nuclearmem-
brane through heterochromatic structures (25, 26), coincides with
chromatin condensation and DNA fragmentation in apoptotic cells.
Although the breakdown of internal nuclear structures is a prerequisite
for chromatin condensation and DNA fragmentation (27, 28), it has
been proposed that themaintenance of high order chromatin structures
is essential for proper chromatin condensation (29). In fact, drugs that
modify chromatin structure are able to block apoptotic chromatin con-
densation (30).
In this report, we have focused our attention on the global character-
ization of histone modification and DNA methylation changes associ-
ated with the apoptotic process, in particular in connection with the
release of nuclear material to the cytosol. Significant global deacetyla-
* This work was supported by Grants SAF 2001-0059, BFU2004-02073/BMC and Ramon y
Cajal Programme (MCYT), and GR/SAL/0224/2004 (Government of Madrid). The costs
of publication of this article were defrayed in part by the payment of page charges.
This article must therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains supple-
mental Fig. S1.
1 Present address: Section of Haematological Oncology, Inst. of Cancer Research, Lon-
don, UK.
2 To whom correspondence may be addressed. E-mail: mesteller@cnio.es.
3 To whom correspondence may be addressed: Cancer Epigenetics Laboratory, Molecu-
lar Pathology Programme, Spanish National Cancer Centre, Melchor Fernández Alma-
gro 3, 28029 Madrid, Spain. Tel.: 34-912-246-900; Fax: 34-912-246-923. E-mail:
eballestar@cnio.es.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 19, pp. 13540 –13547, May 12, 2006
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
13540 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281 • NUMBER 19 • MAY 12, 2006
This is an Open Access article under the CC BY license.
tion of histones H3 and H4 associated with its release during apoptosis
has been observed. Most interestingly, we have identified a unique pat-
tern of post-translational modifications that is characteristic of histones
released early on in apoptosis. Released histone H4 is specifically
hypoacetylated and trimethylated at Lys-20, whereas released histone
H3 is hypoacetylated, demethylated, and dephosphorylated. These his-
tones are released and cofractionate with internucleosomally frag-
mented DNA with a greater 5-methylcytosine content than the DNA
that remains in the nucleus. This released DNA originates in the het-
erochromatic perinuclear region of the cell. These data, together with
the observed pattern of modification of released histones, suggest that
the released material results from the degradation of perinuclear het-
erochromatin and internal structures of the nucleus early on in
apoptosis.
EXPERIMENTAL PROCEDURES
Materials—Jurkat andHL60 cells were grown inDulbecco’smodified
Eagle’s medium supplemented with 10% heat-inactivated fetal bovine
serum. The following rabbit polyclonal antibodies were used: anti-his-
tone H3 (Abcam) directed against a C-terminal peptide of H3, anti-
dimethyl Lys-4 histone H3 (Upstate Biotechnologies, Inc.), anti-di-
methyl Lys-9 histone H3 (Upstate Biotechnologies, Inc.), anti-phospho
Ser-10 histone H3 (Upstate Biotechnologies, Inc.), anti-acetyl histone
H3 (Upstate Biotechnologies, Inc.), anti-acetyl Lys-9 histone H3
(Abcam), anti-acetyl histone H4 (Upstate Biotechnologies, Inc.), anti-
acetyl Lys-5 histoneH4 (Abcam), anti-acetyl Lys-8 histoneH4 (Abcam),
anti-acetyl Lys-12 histone H4 (Upstate Biotechnologies, Inc.), and anti-
acetyl Lys-16 histoneH4 (Upstate Biotechnologies, Inc.). Camptothecin
and etoposide (Sigma) were used as apoptosis inducers. Apoptosis was
analyzed using the Vybrant apoptosis assay kit, 4-YO-PRO-1/pro-
pidium iodide (Molecular Probes/Invitrogen). This kit is based on the
use of the green fluorescent YO-PRO-1 dye that specifically stains
apoptotic cells that remain impermeant to propidium iodide (a dead cell
stain). Live cells are not stained with YO-PRO-1. Cells are then sorted
by flow cytofluorometry.
Induction of Apoptosis—Jurkat and HL60 cells were exposed to 100
M etoposide or 2g/ml of camptothecin and incubated for 3–8 h (30).
Apoptosis was monitored by flow cytometry.
Isolation of Histones—Histones were extracted from cell pellets by
acid extraction on 0.25MHCl followed by acetone precipitation (31). To
investigate the release of histone to the cytosolic fraction during apo-
ptosis, we performed hypotonic lysis with 20mM pH 8.0 buffer contain-
ing 150 mM NaCl and 1% Triton X-100 as described in Wu et al. (20).
Two fractions are obtained in this case: a cell lysate, containing the
cytosolic fraction, and a nuclear pellet. In this case, the supernatant
corresponding to the cytosolic fraction was precipitated using 20% tri-
chloroacetic acid on ice for 30 min, centrifuged at 4 °C for 10 min, and
washed once with acetone. Histones were then obtained by acid extrac-
tion as described above.
Quantification of Global Histone Acetylation by High-performance
Capillary Electrophoresis—The degree of histone acetylation was quan-
tified by a modification of a previously described method (32, 33). Indi-
vidual histones were fractionated by reversed-phase high-performance
liquid chromatography (HPLC)4 on a Delta-Pak C18 column (Waters)
eluted with an acetonitrile gradient (20–60%) in 0.3% trifluoroacetic
acid (34) using a BeckmanHPLC gradient system. Purity of histoneswas
measured by PAGE. The non-, mono-, di-, tri-, and tetraacetylated his-
tone derivatives of H3 fraction were resolved by high-performance cap-
illary electrophoresis (HPCE). A non-coated fused silica capillary (Beck-
man-Coulter) (60.2 cm 75.0mm, effective length 50.0 cm)was used in
a CE system (P/ACETMMDQ; Beckman-Coulter) connected to a data
processing station (32 KaratTM Software). The running buffer was 110
mM phosphate buffer, pH 2.0, containing 0.03% (w/v) hydroxylpropyl-
methyl-cellulose. Running conditions consisted of a temperature of
25 °C and an operating voltage of 12 kV. On-column absorbance was
monitored at 214 nm. Before each run, the capillary system was condi-
tioned bywashingwith 0.1MNaOH for 3min and 0.5MH2SO4 for 2min
and equilibrated with the running buffer for 3 min. Samples were
injected under pressure (0.3 psi) for 3 s. Samples were obtained in trip-
licate, and all samples were analyzed in duplicate. Error bars in graphs
represent standard deviation.
Western Blotting—Histones were separated on 15% SDS-PAGE gel
and blotted onto a polyvinylidene difluoride membrane of 22-m pore
size (Immobilon PSQ; Millipore). The membrane was blocked in 5%
milk PBS-T (phosphate-buffered saline with 0.1% Tween-20) and
immunoprobed with antibodies raised against different peptides con-
taining different histonemodifications as described above. The second-
ary antibodies used were goat anti-rabbit conjugated to horseradish
peroxidase (1:3000) (Amersham Biosciences) and sheep anti-mouse
horseradish peroxidase (1:3000). Bands obtained in Western blot were
scanned and analyzed by Quantity One software (Gel Doc 2000; Bio-
Rad). Experiments were performed in triplicate. Semiquantitative sig-
nificance of the differences was estimated by direct comparison of the
obtained values.
Mass Spectrometry Analysis of Histones—Histone H4 global acetyla-
tion and acetylation at the specific lysine 16 site were analyzed by mass
spectrometry. We separated acid-extracted histones by SDS-PAGE,
excised the Coomassie-stained bands corresponding to histone H4,
subjected them to acetylation with D6-acetic anhydride, and finally
digested with trypsin as previously described (35). Supernatants were
collected, vacuum-dried, and redissolved in 0.5 ml of 0.1% trifluoroace-
tic acid.
Matrix-assisted laser desorption ionization time-of-flight MS analy-
sis of the samples was carried out in a mass spectrometer Autoflex
(Bruker Daltonics) in a positive ion reflectormode. Samples were added
to amatrix consisting of 0.5ml of 5mg/ml of 2,5-dihydroxybenzoic acid
in water:acetonitrile (2:1) with 0.1% trifluoroacetic acid. The ion accel-
eration voltage was 20 kV. Each spectrumwas internally calibrated with
the masses of two trypsin autolysis products.
MS/MS analyses were performed in a linear LTQ ion trapmass spec-
trometer (Thermo Finnigan) equipped with a nano-electrospray ioni-
zation source by using coated GlassTip PicoTip emitters (New Objec-
tive). Samples were desalted and concentrated with Zip Tips (Millipore,
Bedford,MA) following themanufacturer’s protocol. The spectrometer
was operated according to themanufacturer’s instructions withmanual
adjustment of the collision energies. Fragment spectra were interpreted
manually.
Global 5-Methylcytosine Quantification—The 5-methylcytosine
(mC) content was quantified by HPCE as previously described (36). In
brief, DNA samples were speed-back preconcentrated to 0.1mg/ml and
enzymatically hydrolyzed in a final volume of 5 ml. Samples were then
directly injected into a BeckmanMDQhigh-performance capillary elec-
trophoresis apparatus, and mC content was determined as the percent-
age of mC of total cytosine: mC peak area  100/(C peak area  mC
peak area). Error bars in graphs represent standard deviation. Data are
representative of three independent experiments.
4 The abbreviations used are: HPLC, high performance liquid chromatography; HPCE,
high-performance capillary electrophoresis; MS, mass spectrometry; mC, methylcytosine.
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Competitive Hybridization of Apoptotic DNA Fractions inMetaphase
Chromosomes—To study the distribution along the chromosomes of
the DNA isolated from nuclear pellet and cell lysate fractions, we mod-
ified the competitive genomic hybridization strategy (37). In this
hybridization, we compared the DNA isolated from each of the frac-
tions (either the cell lysate or the nuclear pellet) with the DNA isolated
from intact cells. The DNA isolated from each of the fractions was
labeled with Spectrum Red dUTP by CGH nick-translation kit (Vysis,
Inc., Downer Grov, IL), and the total genomic DNA was labeled with
Spectrum Green. The metaphases were captured using a fluorescence
microscope (Olympus BX60) equipped with a CCD camera (Photomet-
rics Sensys camera) and then analyzed using the chromofluor image
analysis system (Cytovision; Applied Imaging Ltd, Newcastle, UK).
13–25 chromosomes were analyzed for each hybridization.
Staining with Fluorescent DNA Probes and Fluorescence Microscopy—
Control cells were fixed in 3.7% formaldehyde for 30 min at room tem-
perature or methanol (20 °C) for 1 min and permeabilized with
phosphate-buffered saline-0.5% Triton X-100 for 10 min at room tem-
perature as previously described (38). DNA from the cell lysate fraction
labeled with Spectrum Red was used to hybridize fixed cells. Confocal
optical sections were obtained using a Leica TCS SP confocal micro-
scope (LeicaMicrosystems, Heidelberg GMbH) equipped with krypton
and argon lasers, and images were processed using Adobe Photoshop
5.0 (Adobe Systems Inc., Mountain View, CA).
RESULTS
Global Reduction in Histone Acetylation Occurs during Apoptosis—
As a first screening approach to investigating a potential connection
between epigenetic alterations and nuclear changes in apoptosis, we
analyzed global changes in the modification status of histones during
apoptosis by Western blot. A change in the pattern of histone modifi-
cations could be associated with morphological changes that occur in
the nucleus in apoptosis.We treated Jurkat cells with etoposide and acid
extracted their histones at different times. For each sample, the level of
apoptosis was monitored by flow cytometry (Fig. 1A, bottom). Antibod-
ies against the global hyperacetylated forms of histones H3 and H4 and
others against the monoacetylated form at specific residues of histone
H3 (Lys-9) and histone H4 (Lys-5, -8, -12, and -16) were used. Antibod-
ies against other modifications, such as phospho-Ser-10, dimethyl-
Lys-4 and dimethyl-Lys-9 of histone H3, were also included.
We first observed a significant decrease in global levels of histone H4
acetylation in apoptotic samples (Fig. 1A). However, when looking at
specific lysine residues of H4 only Lys-8 and Lys-16 exhibited a loss of
acetylation during apoptosis. No significant variations of acetylation
were observed at Lys-5 and Lys-12. These results are consistent with
previous reports that also suggest that the acetylation patterns of the
pairs Lys-8 and Lys-16, on one hand, and Lys-5 and Lys-12, on the other,
are coupled (39).
In contrast to H4, no significant changes in acetylation (either global
or site-specific) were observed for histone H3. Also, phosphorylation of
Ser-10 and methylation of Lys-4 and Lys-9 of H3 appeared to remain
stable (Fig. 1A).
Because the only changes observed were associated with acetylation
status, an alternative quantitative approach was used to estimate
changes in histone acetylation of H3 and H4. The method requires the
fractionation of histones by reversed phase HPLC followed by HPCE
separation (35–37). This allows the resolution and quantification of all
acetylated forms of histones H3 and H4. In this analysis, for histone H4
each of the non-,mono-, di-, tri-, and tetraacetylated histone derivatives
appeared as a doublet of peaks (Fig. 1B, top panel). The first and second
peaks of the doublet had been previously identified as di- and trimethyl-
Lys-20 histoneH4, respectively (40). Trimethylation of Lys-20 inH4 is a
marker of constitutive heterochromatin (9, 41, 42) and aging (43).
In Jurkat cells, relative losses of about 8 and 4% in the acetylated
species of H4 were observed concomitantly with equivalent increases in
non-acetylated forms for the etoposide (70% apoptosis after 8 h) and
camptothecin (56% apoptosis after 8 h) treatments, respectively. The
results obtained for HL60 cells also showed relative losses of 10 and 5%
of acetylated H4 for the etoposide (78% apoptosis after 8 h) and camp-
tothecin (60% after 8 h) treatments, respectively (Fig. 1C, bottom panel).
In the case of histone H3, treatment of HL60 cells with etoposide and
camptothecin resulted in respective relative losses of 5 and 3% of acety-
lated forms (Fig. 1C, bottom panel). These decreases were concomitant
with an increase in the non-acetylated formofH3. Identical results were
obtained with Jurkat cells (data not shown). These small decreases had
not been observed when using Western blot to detect changes in the
acetylation status of H3, although the HPCE analysis indicated that this
is a very reproducible result. On the other hand, it is possible that the
acetyl-H3 antibody does not detect all acetylated forms (mono-, di-, tri-
and tetra-) that are quantified by HPCE. At any rate, the decrease in
acetylation of H3 was significantly smaller than the variations observed
for H4.
HistoneH4Released fromNuclei Early inApoptosis Is Hypoacetylated
and Trimethylated—Having analyzed the global changes in histone H3
and H4 modifications, we next compared the specific modifications
exhibited by histones that are massively released from the nucleus dur-
ing apoptosis (23) with those that are retained. Thus, we induced apo-
ptosis with etoposide and camptothecin and treated the cells with a lysis
buffer containing 1% Triton X-100 (see “Experimental Procedures”).
Under these conditions, in which cells are lysed but the integrity of
nucleus is preserved (20, 44), it is possible to separate histones released
to the cytosol in apoptosis from those remaining in the chromatin.
Therefore, each sample yielded two fractions that we call cell lysate,
corresponding to the cytosolic fraction and nuclear pellet (Fig. 2).
Histones were virtually absent from the cell lysate of uninduced con-
trol samples (Fig. 3A). In apoptotic samples, we observed a time-de-
pendent increase of histones in the cell lysates, which were in fact
released from the nucleus during apoptosis. The amount of histones
reached about a quarter of that remaining in the pelleted fraction 8 h
after inducing apoptosis (Fig. 3A).
The analysis of H4 by HPCE showed that histones retained in the
nuclear pellet did not exhibit significant differences between control
and apoptotic samples (Fig. 3B), unlike the results obtained when total
histone H4 had been analyzed where there were 5–10% decreases in
acetylated histone H4 (Fig. 1B).
However, a comparison of cell lysates with their corresponding
nuclear pellets showed striking differences in the modification pattern
of histone H4. Histone H4 isolated from cell lysates was found to be
consistently hypoacetylated compared with its counterpart in apoptotic
nuclear pellets, with an up to 15% relative decrease in the acetylated
form of histone H4 during early apoptosis (Fig. 3B). Interestingly, dif-
ferences in H4 acetylation between released and retained histone H4
became smaller at longer incubation times. Thus, shortly after apoptosis
was induced, released histone H4was enriched in hypoacetylated forms
and the proportion of acetylated forms increased as apoptosis advanced,
and the released histones more closely resembled those retained in the
nuclear pellet.
However, the most striking finding about histone H4 modification
profiles was that released and retained H4 fractions exhibited different
patterns of methylation. Most specifically, the characteristic doublets
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corresponding to differentmethylation forms of histoneH4were absent
from both fractions, and whereas the cell lysate exhibited only the tri-
methylated form of histone H4, the nuclear pellet only contained the
dimethylated form for short times after apoptosis induction (Fig. 3C).
This is evident from the comparison of the electropherograms of these
two samples, where each of the single peaks that corresponds to the di-
FIGURE 1. Global analysis of histone modifica-
tions during apoptosis. A, analysis by Western
blot with antibodies against acetyl-H4, acetyl Lys-
16, -12, -8, and -5 H4, and acetyl-H3, acetyl Lys-9
H3, dimethyl Lys-9 H3, dimethyl Lys-4 H3, and
phospho Ser-10 H3 of histones extracted from
HL60 cells at different times after apoptosis induc-
tion with etoposide. Coomassie staining is
included as a loading control. The bottom panel
shows the apoptosis levels quantified by flow
cytometry using YO-PRO (see “Methods”). Error
bars in graphs represent S.D. Data are representa-
tive of three independent measurements. B, the
top panel shows an example of HPCE separation of
acetylated species of histone H4 from HL60 cells.
Each acetylated form appears as a doublet corre-
sponding to two different degrees of methylation
as explained under “Results.” The bottom panel
shows a quantification of the acetylation of his-
tone H4 in HL60 cells treated for 8 h with campto-
thecin and etoposide. C, the top panel shows an
example of HPCE separation of acetylated species
of histone H3 from HL60 cells. The bottom panel
shows a quantification of the acetylation of his-
tone H3 in HL60 cells treated for 8 h with campto-
thecin and etoposide.
FIGURE 2. Scheme depicting the protocol
designed to isolate histones that are released
during apoptosis. A control cell is shown. Cells
are treated with a low salt buffer containing 1%
Triton X-100. Under these conditions, in which
cells are lysed but the integrity of nucleus is pre-
served (20), two fractions are obtained by centrif-
ugation: cell lysate, corresponding to the cytosolic
fraction, and nuclear pellet. In apoptotic cells, a
fraction of histones, released from chromatin, is
present in the cell lysate, and nuclear pellets con-
tain nuclei together with apoptotic bodies.
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and trimethylated forms of H4 had been fractionated during the isola-
tion of the released histones (Fig. 3C).
These data indicated that 3 h after apoptosis induction, almost 100%
of histone H4 was trimethylated in the cell lysate (Fig. 3, D and E). This
specific release of trimethylated H4 was progressively lost as apoptosis
advanced. Indeed, after 6 and 8 h of incubation the relative trimethyla-
tion of released histone H4 dropped to 50 and 25%, respectively, due to
the release of dimethylated H4 species (Fig. 3E).
Therefore, trimethylation and hypoacetylation of histoneH4 are spe-
cific features of the histone fraction released from nuclei during early
apoptosis. This specific enrichment of trimethylated and hypoacety-
lated histones in the released fraction is progressively lost at later stages
after induction of apoptosis, when released histones increasingly more
resemble the histones remaining in the nuclei.
Acetylation Status of Different Residues of Histone H3 and H4
Released during Apoptosis by Western Blot Analysis and Mass
Spectrometry—To better characterize the acetylation status of released
histones, we performed Western blot analysis using antibodies against
global hyperacetylated histonesH3 andH4 and compared apoptotic cell
lysates with nuclear pellets. We also used specific antibodies against
different lysine residues in order to investigate changes in acetylation at
particular sites.
First, a significant decrease of global acetylation, both for histone H3
and H4, was observed in cell lysates when compared with histones iso-
lated from the nuclear pellet (Fig. 4). However, whereas the ratio in
acetylation of histone H3 between cell lysate versus nuclear pellet
remained constant during the course of apoptosis, histoneH4was char-
acterized by a progressive change in this ratio. Thus, whereas H4
retained in the nuclear pellet suffered a progressive decrease in acetyla-
tion, in agreementwith the observations shown above, histoneH4 in the
cell lysate was more acetylated at later times after apoptosis induction.
The analysis of all the acetylable positions of H4 (Lys-5, -8, -12, and
-16) showed that released histoneH4was less acetylated in all cases than
the H4 fraction retained in the nuclear pellet. In a time course experi-
ment, acetylation of Lys-16 and Lys-12 followed a pattern similar to
global acetylation and increased in the cell lysate fraction as apoptosis
advanced, whereas no changes were observed in the acetylation of Lys-8
and Lys-5.
Mass spectrometry analysis of these samples (see supplemental Fig.
S1A) confirmed that histone H4 of the apoptotic cell lysate was
FIGURE 3. Analysis of histones that are released from the nucleus in apoptosis. A, histone fractionation by reversed phase HPLC of nuclear pellet (top panel) and apoptotic cell
lysate (released histone fraction, bottom panel) samples from HL60 control treated with etoposide and captothecin. B, analysis of histone H4 acetylation of cell lysates and nuclear
pellet samples after 3, 6, and 8 h of etoposide treatment. C, HPCE profiles of histone H4 from nuclear pellets and apoptotic cell lysates 3 h after apoptosis induction. D, time course
analysis of the HPCE profiles of histone H4 from cell lysates and nuclear pellets (3, 6, and 8 h after etoposide treatment). H4 HPCE profiles from control samples are also shown in the
top panel. E, relative levels of histone H4 trimethylation from nuclear pellets and cell lysates at 3, 6, and 8 h after etoposide treatment of HL60 cells.
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hypoacetylated relative to control and nuclear pellet samples (as already
shown byWestern blot and HPCE analysis). MS/MS analysis indicated
that almost all detectablemonoacetylationwas found to occur in Lys-16
of histone H4 in all the samples. It can be observed that ion y5 (supple-
mental Fig. S1B), containing residues 13–17 (GGAKR) of histone H4,
was almost completely acetylated in all samples, whereas ion b9, con-
taining residues 4–12 (GKGGKGLGK) of histone H4, was almost com-
pletely deacetylated in all samples (supplemental Fig. 1C) and there was
no increase in acetylation of Lys-16 in cell lysates 3 h after treatment.
On the other hand, released histone H3 generally had a lower level of
modification for all modifications studied; it was less acetylated, meth-
ylated, and phosphorylated thanwere histones isolated from the nuclear
pellet.Whereas the levels of acetylatedH3 remained constant, dimethy-
lated forms of Lys-4 and Lys-9 exhibited a slight increase over time
(Fig. 4).
Internucleosomal Fragmented DNA Released in Apoptosis Is Hyper-
methylatedwith Respect to DNAThat Remains in theNucleus—Histone
methylation and acetylation have been shown to be mechanistically
linked to DNAmethylation (45). Therefore, the observed differences in
histone methylation and acetylation during apoptosis and among frac-
tions (apoptotic cell lysates and nuclear pellets) prompted us to inves-
tigate the existence of changes in DNA methylation during apoptosis.
On the other hand, it is possible that changes inDNAmethylation could
participate in the apoptotic process, in a manner similar to those dem-
onstrated in other processes, like cancer development (46, 47).
First, genomic DNA was obtained by a standard protocol from iso-
lated nuclei of HL60 cells treated with etoposide at different times. The
analysis of the 5-methylcytosine content of the samples showed a time-
dependent decrease. The amount of total 5-methylcytosine genomic
content decreased from 3.1% in control cells to 2.4% 6 h after apoptosis
induction (Fig. 5A). These changes, although apparently small, occurred
within the same range of changes experienced during tumoral processes
(48, 49). The observed decrease in the 5-methylcytosine content of
DNA isolated from nuclei could be explained if fractionation of the
DNA between the nucleus and cytosol occurred during apoptosis, sim-
ilar to the fractionation observed for histone modifications.
We therefore isolated DNA from the two fractions: nuclear pellet,
which would account for the DNA isolated previously from the nuclei,
and cell lysate, where the DNA released during apoptosis should be
present. DNAwas quantified and analyzed by agarose gel electrophore-
sis. Interestingly, we observed the characteristic apoptotic internucleo-
somal fragmentation pattern (together with large chromatin fragments
of 5 kbp) only in the DNA isolated from the apoptotic cell lysate,
whereas the DNA from the apoptotic nuclear pellet exhibitedmuch less
fragmentation (Fig. 5B).
DNA isolated from the apoptotic and control cell lysate fractions was
then analyzed by HPCE to measure its 5-methylcytosine content. The
data obtained showed enrichment in methylation in the apoptotic cell
lysate, whereas there were no significant differences among the nuclear
pellet samples (Fig. 5C). DNA corresponding to apoptotic cell lysates
had a content of 5-methylcytosine of 3.5% (Fig. 5C), which was signif-
FIGURE 4. Western blot analysis of histone modifications of apoptotic cell lysate and
nuclear pellet fractions. Analysis with antibodies against acetyl-H4 and acetyl Lys-16,
-12, -8, and -5 H4 of histones extracted from HL60 cells at different times after apoptosis
induction with etoposide. Coomassie staining is included as a loading control.
FIGURE 5. Analysis of DNA that cofractionates with histones released in apoptosis.
A, analysis of 5-methylcytosine content during apoptosis in HL60 cells as quantified by
HPCE. B, analysis by agarose electrophoresis of DNA isolated from the corresponding
nuclear pellet and cell lysate samples of HL60 cells non-treated and treated for 8 h with
etoposide. C, analysis of 5-methylcytosine content of DNA from nuclear pellet and cell
lysate samples of control HL60 and at 3, 6, and 8 h after etoposide treatment. D, 4,6-
diamidino-2-phenylindole and nuclear-specific sequence localization of fragmented
DNA isolated from the apoptotic cell lysate labeled with Spectrum Red in HL60 cells.
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icantly higher than that of the cell line. This percentage is compatible
with that found in chromatin regions with a high percentage of CpG
dinucleotides, i.e. repetitive sequences and/or CpG islands of tumor-
suppressor genes, which aremethylated inHL60 cells. The hypermethy-
lated status of released DNA, together with the hypoacetylation of the
histones and trimethylation of H4 isolated in the same fraction, implies
that the heterochromatin may be the source of the DNA and histones
released during apoptosis.
DNA Released during Apoptosis Comes from Perinuclear Regions
Associated with Heterochromatin—To investigate the origin of the
nuclear material released during apoptosis, DNA isolated from the
apoptotic cell lysate fractionwas labeled with SpectrumRed and used as
a probe to investigate the chromosomal origin of DNA released during
apoptosis. In this case, Spectrum Red-labeled DNA from the cell lysate
fraction was competitively hybridized against total DNA from HL60
cells in metaphase chromosomes. The presence of an even pattern of
labeling throughout all the chromosomes (not shown) did not allow
concluding that released DNA had a preferential chromosomal origin.
We then used Spectrum Red-labeled released DNA in sequence-spe-
cific nuclear fluorescence localization in HL60 cells. This technique can
be used to locate the nuclear origin of the fragmented DNA using a
control non-treated cell as a target. The nuclear localization of theDNA
associated with the apoptotic lysate revealed the formation of fluores-
cent rings at the nuclear periphery, indicating that the released DNA
originated in the perinuclear region of the nucleus where chromatin
interacts with the nuclear membrane mainly through heterochromatin
sequences (25, 26, 50, 51) (Fig. 5D). This result is compatible with those
obtained after the 5-methylcytosine analysis of the released DNA that
had already indicated a possible heterochromatic origin.
DISCUSSION
Histone modifications play key roles in different cellular processes,
including replication, transcription, DNA repair, and chromatin con-
densation in mitosis (3). Several of the most recognizable events in
apoptosis involve visible changes in the nucleus, including chromatin
condensation, DNA fragmentation, and release of nuclear proteins (2,
20). It is very likely that histone modifications participate in these pro-
cesses and probably coordinate and connect these events. Here we have
demonstrated that changes in histone modifications do indeed occur in
apoptotic cells, and we propose that a specific pattern of histone mod-
ifications existing before apoptosis could participate in events such as
the release of nuclear material.
Global Histone Hypoacetylation in Apoptosis—Our results support
the notion that global histone hypoacetylation occurs during apoptosis.
Interestingly, hypoacetylation does not seem to be a passive apoptotic
characteristic, because it is clearly associated with a fraction of the his-
tones released from chromatin during its degradation. This observation
directly associates histone hypoacetylation with the structural changes
in chromatin taking place during apoptosis and its degradation.
It has been previously proposed (19) that global decrease of histone
acetylation could be the result of a selective loss through proteolytic
degradation in the cytosol of hyperacetylated histones released from
euchromatin during early apoptosis and that this would cause a net
increase in apparent global hypoacetylation. However, our results indi-
cate that histones released during early apoptosis show significantly
more hypoacetylation than do those remaining in the nucleus. A differ-
ential analysis of the apoptotic cell lysates, where the released histones
are present, and nuclear pellets shows that global hypoacetylation
mainly occurs in the released fraction, indicating that released histones
come preferentially from hypoacetylated and not hyperacetylated chro-
matin. Although this experiment does not rule out the possibility of
specific degradation of hyperacetylated histones, Western blot analyses
of the samples from both cell lysate and nuclear pellet do not show
significant degradation of histones H3 and H4 (Fig. 1A).
Trimethylation of Histone H4 Is Specifically Associated with Histones
Released during Apoptosis—One of the most striking findings of this
study is that the fraction of histone H4 released from chromatin in early
apoptosis is exclusively trimethylated. This trimethylation has been pre-
viously demonstrated to occur at Lys-20 (40).
Although it is likely that H4 Lys-20 trimethylation acts as a passive
feature or structural determinant for chromatin degradation and
release, we cannot discount the possibility that it may play an active role
as a recruiting signal for nuclear factors or nucleases in these processes.
Thus, histone H4 trimethylation could act as a signal in a way similar to
other post-translational modifications that recruit different nuclear
complexes to chromatin (52, 53) in the context of the histone code (54).
Trimethylation at Lys-20, alone or in combination with other modifica-
tions such as acetylation, could then act as a signal for enzymes that are
capable of inducing DNA fragmentation and/or chromatin condensa-
tion, either directly in the case of nucleases that cleave DNA or indi-
rectly if the recruited enzymes are associated with chromatin remodel-
ing activities.
Released Histones and DNA during Early Apoptosis Have Their Ori-
gin in the Perinuclear Heterochromatin—The identity of the epigenetic
marks and experiments to localize histones and DNA isolated from
apoptotic cell lysates indicate that the material released from the
nucleus in apoptosis has a perinuclear origin, at least during the initial
stages. First, released DNA isolated from apoptotic cell lysates is hyper-
methylated and, when labeled and used as a probe for staining, exhibits
perinuclear localization. On the other hand, released histones are
hypoacetylated and histone H4 is trimethylated at Lys-20, a character-
istic epigenetic mark of constitutive heterochromatin (8, 9, 41, 43, 55).
In fact, we have previously demonstrated that trimethylated histone H4
at Lys-20 is associated with satellite and other repetitive sequences (40)
that are known to be part of constitutive heterochromatin.
Internal nuclear structures become degraded before apoptotic chro-
matin condensation and DNA fragmentation, (22–24, 28). These
include heterochromatin structures by which chromatin is anchored to
the nuclear membrane (25, 26, 51, 56). This is even stronger evidence in
support of the hypothesis that histone H4 and fragmented DNA
released and isolated in the cell lysate fraction are a direct consequence
of the perinuclear heterochromatin degradation described.
It has been proposed that chromatin condensation during apoptosis
consists of a process of several consecutive steps. In the first step, endo-
nuclease-hypersensitive euchromatin, which is hyperacetylated, would
be degraded, followed or accompanied by the degradation of both the
nuclear lamina and components of the intranuclear proteinmatrix dur-
ing early apoptosis. The collapse and aggregation of heterochromatin
would follow, giving rise to the characteristic apoptotic chromatin con-
densation. Afterward, there would be a second degradation process of
the heterochromatin that would yield the characteristic oligonucleoso-
mal DNA ladder (19). Therefore, should this model be correct, the
majority of the apoptotic cell lysate histones and DNA would be the
product of the heterochromatin collapse and degradation process, most
probably from the perinuclear heterochromatin region degraded along
the nuclear lamina. We have not been able to identify the presence of
hyperacetylated histones in the apoptotic cell lysate during early apo-
ptosis prior to the hypoacetylated and trimethylated histone H4 release.
Therefore, this model implies that no histones or DNA are released
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from euchromatin degradation even if this occurs before heterochro-
matin collapse and degradation takes place.
The unique content of epigenetic modifications in histone and DNA
released during apoptosis and characterized by the methylation and
acetylation status of histone H4 from perinuclear heterochromatin and
hypermethylation of DNA suggests that these modifications may pro-
vide cells with the adequate context, perhaps by the formation of spe-
cific nuclear structures, specific substrates, or both, to initiate the deg-
radation of the nucleus in apoptosis and to control chromatin
condensation.
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